Investigators systematically evaluate the efficacy differences of existing treatment regimens for IgA nephropathy.

Purespring Therapeutics has received approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002, to treat IgA nephropathy (IgAN). Approval from the UK ...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval ...

Q2 2025 Earnings Call Transcript August 6, 2025 Travere Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Management expects continued revenue growth driven by robust FILSPARI demand in IgA nephropathy and potential additional milestone payments. Cline said, "we expect continued revenue growth driven by ...

IgA Nephropathy Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key IgAN companies such ...

On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; ...

Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON (R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This ...

Now, it’s worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for ...

Last winter, I donated my kidney to a stranger. As a nephrologist, I see people every day who need a gently used kidney, and having two myself, I could not see fit to hold on to both. The experience ...

Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R)'is ...

My illness previously dictated how I planned my days, years and entire sense of possibility – pregnancy has disrupted that ...